Investor Presentation H1 2023

75 Investor presentation First six months of 2023 The CagriSema phase 3 programme, REDEFINE, was initiated in the Q4 2022 REDEFINE 1 trial design REDEFINE 2 trial design CagriSema 2.4 mg/2.4 mg1 N = 3400 N=1200 R 21:3:3:7 Cagrilintide 2.4 mg¹ Semaglutide 2.4 mg1 Placebo¹ CagriSema 2.4 mg/2.4 mg1 R Placebo¹ 3:1 Novo NordiskⓇ Week 0 + 16 68 75 Week 0 + 16 68 75 Dose escalation Treatment maintenance Follow- up Dose escalation Treatment maintenance Follow- up Inclusion criteria REDEFINE 1: • BMI: ≥ 30 kg/m² or ≥ 27 kg/m² and ≥1 comorbidity Excludes diabetes diagnosis or HbA1c ≥ 6.5% . REDEFINE 2: Primary endpoints: Change in body weight (%) Achieve ≥ 5% body weight reduction . BMI: ≥ 27 kg/m² Type 2 diabetes, HbA1c <10% Confirmatory secondary endpoints: . Change in waist circumference HbA1c Systolic blood pressure Patient reported outcomes² 'As an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight. 2 Patient reported outcomes include (IWQOL-Lite-CT, SF-36v2, and Vitality score) CagriSema: Cagrilintide in combination with semaglutide; T2DM: Type 2 diabetes; BMI: Body mass index; HbA₁: Hemoglobin A₁; IWQOL-Lite-CT: Impact of weight on quality of life - lite, clinical trials version; Short form 36v2

View entire presentation